Jiazheng Sun

Jiazheng Sun

Auto-generated profile, based on publicly available information

Jiazheng Sun

Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2024 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
PWPin Wang
Pin Wang
JSJia-Zheng Sun
Jia-Zheng Sun
HFHui-Ying Fang
Hui-Ying Fang
DYDe-Juan Yang
De-Juan Yang
GRGuosheng Ren
Guosheng Ren
Background: Idiopathic granulomatous mastitis (IGM) is a chronic breast condition known for its aggressive nature and tendency for persistence and recurrence. Steroids are commonly used as the first-line treatment for IGM, but issues such as the optimal timing, and duration of treatment remain debated. Methods: We retrospectively analyzed 343 IGM cases treated at the Third People’s Hospital of Chengdu from September 2012 to September 2023. Based on inclusion and exclusion criteria, a total of 188 patients were included in the study. Patients were categorized into lump (78 cases), abscess (81 cases), and sinus tract stages (29 cases) according to their initial diagnosis upon admission. Prednisolone was initiated at 0.75 mg/kg/day, and after effective treatment, the dosage was adjusted by 5– 10 mg weekly, followed by a maintenance dose of 2.5– 5 mg/day. Clinical characteristics, treatment responses, adverse effects, recurrence rates, and follow-up data were assessed. Results: The median duration of prednisone treatment in our study was 87 days (range, 21– 281 days). Positive response rates to prednisolone were 78.2% in the lump stage, 60.5% in the abscess stage, and 62.1% in the sinus tract stage. Continuing low-dose prednisone for 3 months post-effective treatment reduced recurrence rates and side effect risks. Weight gain was the most common side effect (39.36%). Conclusion: Early steroid therapy, especially in the lump stage, demonstrated superior efficacy. Following a regimen of starting with a full dose, tapering slowly, and maintaining a low dose for around 3 months steroids treatment is recommended to minimize recurrence rate and adverse effects.

27 November 2024 in Cancer Immunology Research
Verified
Journal Article
Open access
JSJiazheng Sun
Jiazheng Sun
PWPin Wang
Pin Wang
ZYZiying Yi
Ziying Yi
YWYushen Wu
Yushen Wu
WXWei Yu xian
Wei Yu xian
HLHongzhong Li
Hongzhong Li
The limited infiltration of CD8+ T cells in tumors hampers the effectiveness of T cell–based immunotherapy, yet the mechanisms that limit tumor infiltration by CD8+ T cells remain unclear. Through bulk RNA sequencing of human tumors, we identified a strong correlation between WNT7A expression and reduced CD8+ T-cell infiltration. Further investigation demonstrated that inhibiting WNT7A substantially enhanced MHC-I expression on tumor cells. Mechanistically, WNT7A inhibition inactivated the Wnt/β-catenin signaling pathway and thus resulted in reduced physical interaction between β-catenin and p65 in the cytoplasm, which increased the nuclear translocation of p65 and activated the NF-κB pathway, ultimately promoting the transcription of genes encoding MHC-I molecules. We found that our lead compound, 1365-0109, disrupted the protein–protein interaction between WNT7A and its receptor FZD5, resulting in the upregulation of MHC-I expression. In murine tumor models, both genetic and pharmaceutical suppression of WNT7A led to increased MHC-I levels on tumor cells, and consequently enhanced the infiltration and functionality of CD8+ T cells, which bolstered antitumor immunity and improved the effectiveness of immune checkpoint blockade therapy. These findings have elucidated the intrinsic mechanisms of WNT7A-induced immune suppression, suggesting that therapeutic interventions targeting WNT7A hold promise for enhancing the efficacy of immunotherapy.

4 March 2025
Verified
Other
Open access
JSJiazheng Sun
Jiazheng Sun
PWPin Wang
Pin Wang
ZYZiying Yi
Ziying Yi
YWYushen Wu
Yushen Wu
WXWei Yu xian
Wei Yu xian
HLHongzhong Li
Hongzhong Li
Figure S2 Blocking WNT7A leads to an increase in MHC-I expression.

4 March 2025
Verified
Other
Open access
JSJiazheng Sun
Jiazheng Sun
PWPin Wang
Pin Wang
ZYZiying Yi
Ziying Yi
YWYushen Wu
Yushen Wu
WXWei Yu xian
Wei Yu xian
HLHongzhong Li
Hongzhong Li
Figure S4 Inhibition of WNT7A leads to the upregulation of MHC-I via the NF-κB pathway.

4 March 2025
Verified
Other
Open access
JSJiazheng Sun
Jiazheng Sun
PWPin Wang
Pin Wang
ZYZiying Yi
Ziying Yi
YWYushen Wu
Yushen Wu
WXWei Yu xian
Wei Yu xian
HLHongzhong Li
Hongzhong Li
Figure S3 WNT7A blockage inhibits tumor growth and enhances anti-tumor immunity.

4 March 2025
Verified
Other
Open access
JSJiazheng Sun
Jiazheng Sun
PWPin Wang
Pin Wang
ZYZiying Yi
Ziying Yi
YWYushen Wu
Yushen Wu
WXWei Yu xian
Wei Yu xian
HLHongzhong Li
Hongzhong Li
Figure S5 Blocking WNT7A synergizes with ICB.